Lamogine

/ Trima

See prescribing information for full details.

Epilepsy: Monotherapy in adults and children over 12 years of age: Simple partial seizures, complex partial seizures, secondary generalized tonic-clonic seizures, primary generalized tonic-clonic seizures. Monotherapy in children under 12 years of age is not recommended.
Add-on-therapy in adults and children over 2 years of age: Simple partial seizures, complex partial seizures, secondary generalized tonic-clonic seizures.

Known hypersensitivity to lamotrigine.

As with other AED’s, abrupt withdrawal may provoke rebound seizures. Should be gradually decreased over a period of two weeks. Caution should be exercised when dosing severely hepatically impaired population. Adverse skin reactions, which have generally occurred within the first eight weeks after initiation of lamotrigine. The majority of rashes are mild and self limiting. Stevens Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported.

Monotherapy: Headache, tiredness, rash, nausea, dizziness, drowsiness, insomnia. Add-on therapy: Diplopia, blurred vision, conjunctivitis, dizziness, drowsiness, headache, unsteadiness, tiredness, GI disturbances (including nausea and vomiting), irritability/aggression, tremor, agitation, confusion, hematological abnormalities (including leukopenia and thrombocytopenia).

Phenytoin, carbamazepine, phenobarbitone, primidone.